{"entity":{"id":"lapiteronel","kind":"drug","name":"Lapiteronel","aka":["LAE001"],"tldr":"Lapiteronel is an experimental pill from Laekna Therapeutics, in phase 2 trials for metastatic castration-resistant prostate cancer.","summary":"Lapiteronel (LAE001) is a small molecule from Laekna Therapeutics. Blocks CYP17A1 and CYP11B2, enzymes that make androgen and aldosterone hormones. Laekna licensed it from Novartis in 2017. Its pipeline lists lapiteronel with afuresertib and prednisone in metastatic castration-resistant prostate cancer as a US phase 3 programme; the registered company trials found are phase 1/2 (NCT04060394, completed, and NCT03843918, terminated). OnCo has no CYP11B2 target record.","status":"phase-2","asOf":"2026-11-04","links":[{"label":"Laekna research and development","url":"https://www.laekna.com/rd"},{"label":"ClinicalTrials.gov NCT04060394","url":"https://clinicaltrials.gov/study/NCT04060394"},{"label":"ClinicalTrials.gov NCT03843918","url":"https://clinicaltrials.gov/study/NCT03843918"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate-mcrpc"],"sections":[],"technologies":[],"targets":["cyp17a1"],"drugs":[],"companies":["laekna-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04060394","nct03843918"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors, investor portfolios (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-04"},"code":"LAE001","modality":"Small molecule","mechanism":"Blocks CYP17A1 and CYP11B2, enzymes that make androgen and aldosterone hormones.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/lapiteronel/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"}],"target":[{"id":"cyp17a1","kind":"target","name":"CYP17A1 (17-alpha-hydroxylase/17,20-lyase)","route":"/targets/cyp17a1/"}],"company":[{"id":"laekna-therapeutics","kind":"company","name":"Laekna Therapeutics","route":"/companies/laekna-therapeutics/"}],"trial":[{"id":"nct03843918","kind":"trial","name":"A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer","route":"/trials/nct03843918/"},{"id":"nct04060394","kind":"trial","name":"Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC","route":"/trials/nct04060394/"}]}}